Discontinuation of Levemir (insulin detemir): Joint guidance from ABCD and PCDO Society

Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.

In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.

Rights and licensing

The authors, ABCD and PCDO Society grant permission for this document, or specific content within it, to be reused in educational activities. An appropriate acknowledgement must be displayed, along with a link to this URL.

Citation: Newland-Jones P, Beba H, Kanumilli N, Kelly B, Lindsay R, Mehta F, Milne N, Platts J, Tahir W, Dhatariya K (2025) Discontinuation of Levemir® (Insulin detemir) Flexpen® and Penfill® Clinical Guideline. Primary Care Diabetes & Obeisty Society and Association of British Clinical Endocrinologists. Available at: https://pcdosociety.org/guidance/levemir-discontinuation